Group 1 - Pollon Life, a Chinese stem cell therapy development company, has confidentially applied for a listing in Hong Kong, aiming to raise approximately $300 million [1] - The company is supported by Jack Ma's Yunfeng Capital and is collaborating with Jianyin International, China International Capital Corporation (CICC), and UBS Group to advance its IPO plans, with discussions still ongoing and potential adjustments to the IPO scale and details [1] - Pollon Life, previously known as Platinum Biotech, developed China's first approved stem cell therapy, Aimi Maitosai injection, which is indicated for treating acute graft-versus-host disease primarily affecting the digestive tract in patients over 14 years old who have failed hormone therapy [1]
传干细胞疗法开发企业Pollon Life秘密申请香港上市 募资约3亿美元
Zhi Tong Cai Jing·2025-10-29 05:57